
Spero Therapeutics, Inc.
- Jurisdiction
United States - LEI
54930074G13LHWJT2323 - ISIN
US84833T1034 (SPRO )- Sectors
Scores
- Fair value (Benjamin Graham formula)
- N/A
- Financial strength (Piotroski F-Value)
-
3
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
2
/ 7
Profile
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. Read full profile
Fundamentals
- Net revenue
€34.55M - Gross margin
100.0% - EBIT
-€49.04M - EBIT margin
-142.0% - Net income
-€46.46M - Net margin
-134.5%
Statement period: - (published )
Stock price
Dividends
- Last dividend amount
-
$0.02 - Ex date
-
- Payment date
-
Analyst ratings
No analyst ratings available
Insider Transactions
Name | Title | Transaction Date | Shares | Price | Value |
---|---|---|---|---|---|
Keutzer Timothy | Chief Operating Officer |
|
|
|
|
Mahadevia Ankit | N/A |
|
|
|
|
Earnings Calls
Investor transactions
Name | Shares | Value | Last change | Change type |
---|---|---|---|---|
Peter Brown |
|
|
|
Sell |
Earnings Calls
Latest earnings call: March 13, 2024 (Q4 2023)